Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | Director | August 08, 2018 | August 10, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date August 08, 2018 · Filed August 10, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,212 |
Ending reported balance
After 2018-08-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-08-08 · Exercise / conversion · Acquired 5,000 · Balance 13,212 Row 2 · 2018-08-08 · Sale · Disposed 5,000 · Balance 8,212 |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.06 · Expires 2019-10-28 | Direct | 0 |
Reported balance
After 2018-08-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-08-08 · Exercise / conversion · Disposed 5,000 · Balance 0 |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $125.05 · Expires 2027-10-26 | Direct | 3,125 |
Reported balance
Holding disclosure · report date 2018-08-08 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 3,125 F1: The option vests on the earlier of the one year anniversary of the grant date (10/26/17) or the date of Bio-Techne's 2018 annual meeting of shareholders. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $101.19 · Expires 2026-10-26 | Direct | 3,985 |
Reported balance
Holding disclosure · report date 2018-08-08 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 3,985 |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $87.34 · Expires 2025-10-28 | Direct | 4,260 |
Reported balance
Holding disclosure · report date 2018-08-08 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 4,260 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $91.78 · Expires 2024-10-30 | Direct | 4,000 |
Reported balance
Holding disclosure · report date 2018-08-08 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 4,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $87.39 · Expires 2023-10-30 | Direct | 4,000 |
Reported balance
Holding disclosure · report date 2018-08-08 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 4,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.35 · Expires 2021-10-26 | Direct | 5,000 |
Reported balance
Holding disclosure · report date 2018-08-08 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 5,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.90 · Expires 2022-10-24 | Direct | 5,000 |
Reported balance
Holding disclosure · report date 2018-08-08 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 5,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.47 · Expires 2018-10-22 | Direct | 5,000 |
Reported balance
Holding disclosure · report date 2018-08-08 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 5,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.46 · Expires 2020-10-27 | Direct | 5,000 |
Reported balance
Holding disclosure · report date 2018-08-08 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 5,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of the one year anniversary of the grant date (10/26/17) or the date of Bio-Techne's 2018 annual meeting of shareholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 08, 2018 Filed Aug 10, 2018 20:18 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to buy) · Derivative | 5,000 | $0.00 Strike: $63.06 | $0.00 |
DisclosureSEC source: 0001562180-18-003560 · primarydocument.xml · derivative · entry 3 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2019-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2018 Filed Aug 10, 2018 20:18 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 5,000 | $176.94 | $884,675.00 |
DisclosureSEC source: 0001562180-18-003560 · primarydocument.xml · nonDerivative · entry 2 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,212 Read SEC document |
| August 08, 2018 Filed Aug 10, 2018 20:18 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 5,000 | $63.03 | $315,150.00 |
DisclosureSEC source: 0001562180-18-003560 · primarydocument.xml · nonDerivative · entry 1 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 21:02 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $65.47 | $0.00 |
DisclosureSEC source: 0000914190-18-000041 · edgar.xml · derivative · entry 13 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2018-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 21:02 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 2,505 | $136.36 | $341,581.80 |
DisclosureSEC source: 0000914190-18-000041 · edgar.xml · nonDerivative · entry 3 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,212 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.03 to $136.66, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 21:02 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 2,495 | $135.76 | $338,721.20 |
DisclosureSEC source: 0000914190-18-000041 · edgar.xml · nonDerivative · entry 2 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,717 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.61 to $135.875, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 21:02 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 5,000 | $65.47 | $327,350.00 |
DisclosureSEC source: 0000914190-18-000041 · edgar.xml · nonDerivative · entry 1 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:46 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to buy) · Derivative | 3,125 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003373 · primarydocument.xml · derivative · entry 2 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 Underlying: Common Stock · 3,125 shares Expires 2027-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/2017) or the date of Bio-Techne 2018 annual meeting of shareholders. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:46 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 739 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003373 · primarydocument.xml · nonDerivative · entry 1 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,212 Read SEC document |
| May 31, 2017 Filed May 31, 2017 20:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 5,000 | $111.37 | $556,861.50 |
DisclosureSEC source: 0001562180-17-002102 · primarydocument.xml · nonDerivative · entry 2 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,473 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.3699 to $111.3790, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 26, 2017 Filed May 31, 2017 20:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to buy) · Derivative | 5,000 | $0.00 Strike: $66.59 | $0.00 |
DisclosureSEC source: 0001562180-17-002102 · primarydocument.xml · derivative · entry 3 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2017-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2017 Filed May 31, 2017 20:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 5,000 | $66.59 | $332,950.00 |
DisclosureSEC source: 0001562180-17-002102 · primarydocument.xml · nonDerivative · entry 1 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:16 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 3,985 | $0.00 Strike: $101.19 | $0.00 |
DisclosureSEC source: 0000914190-16-000858 · edgar.xml · derivative · entry 2 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,985 Underlying: Common Stock · 3,985 shares Expires 2026-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/17) or the date of Bio-Techne's 2017 annual meeting of shareholders. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:16 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 914 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-16-000858 · edgar.xml · nonDerivative · entry 1 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,473 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.